Peripheral T-cell Lymphoma
8 competing products in clinical development for Peripheral T-cell Lymphoma.
Pipeline by Phase
Phase 11
Phase 1/21
Phase 25
Phase 31
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| E7777 | Eisai | Phase 2 | Completed | 35 |
| Ontak + CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy | Eisai | Phase 2 | Completed | 35 |
| KW-0761 (mogamulizumab) | Kyowa Kirin | Phase 2 | Completed | 35 |
| KW-0761 | Kyowa Kirin | Phase 2 | Completed | 35 |
| E7777 | Eisai | Phase 3 | Withdrawn | 32 |
| KW-0761 | Kyowa Kirin | Phase 1/2 | Completed | 32 |
| denileukin diftitox (E7777) | Eisai | Phase 1 | Completed | 29 |
| Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox | Eisai | Phase 2 | Terminated | 27 |